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KEYNOTE-012 was a phase Ib, multicohort study designed to investigate efficacy and
safety of pembrolizumab in advanced solid tumors. Results from the subset of patients
with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the
Asia-Pacific region are reported. Patients with recurrent/metastatic HNSCC, measur-
able disease (RECIST version 1.1), and ECOG performance status (PS) 0-1 were eligible
for enrollment in the HNSCC expansion cohort. Patients received pembrolizumab
200 mg every 3 weeks. Response was assessed every 8 weeks. Co-primary end-points
were safety and overall response rate (RECIST version 1.1, central review). Secondary
end-points included overall survival and response duration. Patients enrolled at any of
the five centers throughout the Asia-Pacific region were included in these analyses.
Twenty-six patients with HNSCC from the Asia-Pacific region received pembrolizumab.
The median age was 62 years, 65% of patients had ECOG PS 1, and 62% had received
two or more prior therapies for recurrent/metastatic disease. Sixteen (62%) patients
experienced a treatment-related adverse event of any grade, including two (8%) patients
who experienced one or more events of grade 3 severity. No treatment-related deaths
occurred. The overall response rate was 19% (95% confidence interval, 7%-39%). After
a median follow-up of 12 months (range, 2-21 months), a median response duration
was not reached (range, 6 to 17+ months); four of five responses lasted ≥6 months.
Median overall survival was 11.6 months (95% confidence interval, 4.7-17.7 months).
Pembrolizumab was well tolerated and had durable antitumor activity in patients with
HNSCC from the Asia-Pacific region. (Trial registration no. NCT01848834.)
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1 | INTRODUCTION
Head and neck squamous cell carcinoma poses a significant public
health burden in the Asia-Pacific region. The global incidence of
Abbreviations: AE, adverse event; CI, confidence interval; CPS, combined positive score;
CR, complete response; DOR, duration of response; HNSCC, head and neck squamous cell
carcinoma; ORR, overall response rate; OS, overall survival; PD, progressive disease; PD-1,
programmed death-1; PD-L1, programmed death ligand-1; PFS, progression-free survival;
PR, partial response; PS, performance status.
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HNSCC tops 600 000 cases annually, with more than half of all
cases originating in the Asia-Pacific region.1-3 In addition to the tra-
ditional HNSCC risk factors (ie, tobacco and alcohol use and human
papillomavirus infection),4,5 other cultural influences, such as the
chewing of betel nut, the consumption of products high in nitroso
compounds, and exposure to Epstein–Barr virus, contribute to an
increase in the occurrence of HNSCC in this region.6-8
In Asia, a multimodal approach that combines platinum-based
chemotherapy, radiotherapy, and another agent (preferably cetux-
imab), is recommended for the treatment of patients with recurrent/
metastatic HNSCC.9 However, the concomitant use of cisplatin and
cetuximab in advanced HNSCC is associated with substantial toxic-
ity,10 and therefore its use is limited in vulnerable populations, such
as the elderly.9 Although there are no standard alternatives, other
commonly used second-line treatments (eg, methotrexate or taxanes)
are often plagued by low response rates (ranging from 3% to
13%).5,11 Thus, there is an unmet need in recurrent/metastatic
HNSCC for treatment options that are both well tolerated and
effective.
The PD-1 pathway is an important immune checkpoint that has
been established as an effective target in HNSCC.12-15 Pem-
brolizumab, an anti-PD-1 antibody, has shown robust antitumor
activity and a manageable safety profile in multiple tumor types, and
is currently approved for one or more advanced malignancies, includ-
ing in the USA for patients with recurrent or metastatic HNSCC with
disease progression on or after platinum-containing chemotherapy.16
This approval was based on efficacy and safety outcomes from the
phase Ib multicohort KEYNOTE-012 trial (ClinicalTrials.gov,
NCT01848834).16 KEYNOTE-012 included two HNSCC cohorts. The
initial cohort (n = 60) enrolled only patients with PD-L1-positive
tumors, and pembrolizumab 10 mg/kg was given every 2 weeks.12
The expansion cohort (n = 132) enrolled patients regardless of PD-
L1 status, and pembrolizumab 200 mg was given every 3 weeks.13
The confirmed ORR in both cohorts was 18%, and responses were
durable.12,13 After a median follow-up of 14 months and 9 months
in the initial and expansion cohorts, respectively, the median DOR
was 53 weeks in the initial cohort and was not reached in the
expansion cohort.12,13 Additionally, pembrolizumab was well toler-
ated in both cohorts, with treatment-related AEs of grade 3-4 sever-
ity occurring in 17% and 9% of patients, respectively.12,13
The HNSCC expansion cohort of KEYNOTE-012 included
patients from the Asia-Pacific region. Here, we report the outcomes
of this subgroup of patients.
2 | MATERIALS AND METHODS
2.1 | Patients
KEYNOTE-012 was a phase Ib, multicenter, non-randomized, multi-
cohort trial designed to investigate the safety and efficacy of pem-
brolizumab in patients with advanced solid tumors.12,13,17,18 The
study protocol and all amendments were approved by relevant regu-
latory and independent ethics committees. The trial was carried out
in accordance with the Declaration of Helsinki and the International
Conference on Harmonization Good Clinical Practice guidelines. All
patients provided written informed consent before entering the
study.
Detailed eligibility criteria for the HNSCC expansion cohort have
been published elsewhere.13 Briefly, the expansion cohort included
adults (age ≥18 years) with histologically or cytologically confirmed
recurrent, metastatic, or persistent HNSCC, measurable disease per
RECIST version 1.1, ECOG PS of 0 or 1, and adequate organ func-
tion. There was no limit to the number of prior therapies, but prior
treatment with agents targeting T-cell co-stimulation or checkpoint
pathways was not allowed. Prior systemic immunosuppressive ther-
apy, small molecule therapy, and anticancer mAb therapy had to be
concluded within 7 days, 2 weeks, and 4 weeks before the start of
pembrolizumab, respectively. Patients with known additional pro-
gressing malignancies, central nervous system metastases, active
autoimmune disease, interstitial lung disease, hepatitis B or C, or
HIV infection were excluded.
2.2 | Study design
Patients in the expansion cohort received pembrolizumab 200 mg
i.v. every 3 weeks for 24 months or until confirmed PD, unaccept-
able toxicity, investigator decision to withdraw the patient, or patient
decision to withdraw consent. Tumor imaging was carried out by
computed tomography or MRI every 8 weeks, and tumor response
was assessed per RECIST version 1.1. Patients with initial radiologic
evidence of PD could remain on treatment at the discretion of the
investigator until repeat imaging was undertaken no sooner than
4 weeks later. During repeat imaging, if a reduction in tumor burden
compared with what was seen on the initial scan was observed, the
patient could continue on treatment as scheduled. Patients with con-
firmed PD discontinued treatment. Patients who achieved an investi-
gator-determined CR could stop pembrolizumab after receiving at
least 24 weeks of treatment. Patients who discontinued after achiev-
ing a CR or after the completion of 24 months of pembrolizumab
were eligible for up to one additional year of treatment if subse-
quent progression occurred.
Adverse events were monitored throughout the trial and for
30 days after the end of treatment. Monitoring for serious AEs and
immune-mediated AEs, defined as events with potentially drug-
related immunologic causes regardless of attribution to treatment by
the investigator, was continued for 90 days after treatment end.
Adverse events were graded according to the NCI’s Common Termi-
nology Criteria for Adverse Events version 4.0. Pembrolizumab was
withheld for grade 3 treatment-related AEs and severe AEs until tox-
icity resolved to grade 0/1. If toxicity did not resolve within
12 weeks, treatment was discontinued. Treatment was also discon-
tinued for grade 4 treatment-related AEs.
The co-primary end-points were safety and ORR per RECIST ver-
sion 1.1 by central imaging vendor review. Secondary end-points
included ORR by RECIST version 1.1 per investigator assessment,
PFS, OS, and DOR.
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2.3 | Statistical analysis
Efficacy and safety analyses were undertaken in all patients who
received one dose or more of pembrolizumab (all-patients-as-treated
population). The subgroup analysis presented herein was restricted to
patients receiving treatment at a site located in the Asia-Pacific region.
Exact methods for binomial parameters were used to determine
ORR and 95% CIs per RECIST version 1.1. Patients with missing data
were considered non-responders. Kaplan–Meier statistics were used
to estimate PFS, OS, and DOR. Patients with missing survival data
were censored at their last assessment. Non-responders were
excluded from DOR analyses. The data cut-off date for these analy-
ses was April 26, 2016.
3 | RESULTS
3.1 | Patients
In total, 26 patients with HNSCC were enrolled at one of five centers
located in the Asia-Pacific region (National Cancer Center Hospital
East, Kashiwa, Japan; Aichi Cancer Center Hospital, Nagoya, Japan;
Seoul National University Hospital, Seoul, Korea; Severance Hospital,
Seoul, Korea; and National Taiwan University Hospital, Taipei, Taiwan).
The median age was 62 years (range, 44-73 years), 85% of patients
were male, and 65% had ECOG PS 1 (Table 1). With regard to tradi-
tional HNSCC risk factors, the majority of patients had a history of
smoking (73%), whereas only two (8%) patients had human papillo-
mavirus-associated disease. Patients were heavily pretreated; 61%
had received two or more prior therapies for recurrent/metastatic dis-
ease and 92% had received prior platinum treatment (Table 1).
Twenty-two (85%) patients had tumors that expressed PD-L1 per a
CPS (number of PD-L1-positive cells [tumor cells, lymphocytes, and
macrophages] divided by the total number of tumor cells 9 100 as
determined by immunohistochemistry) ≥1 (previously reported as and
equivalent to 1%);13 four (15%) patients had tumors that did not
express PD-L1 (CPS <1). At the data cut-off date (April 26, 2016), 23
patients had discontinued pembrolizumab because of PD (n = 21) or
an AE (n = 2); three patients were continuing on treatment.
Median pembrolizumab exposure at the data cut-off was 95 days
(range, 1-617 days). Median follow-up at that time was 12 months
(range, 2-21 months).
3.2 | Safety
Sixteen (62%) patients experienced treatment-related AEs of any
grade, the most common of which were fatigue (n = 5), decreased
appetite (n = 5), hypothyroidism (n = 4), and rash (n = 4) (Table 2).
Two (8%) patients experienced ≥1 grade 3 treatment-related AEs:
one patient had an infection and another experienced decreased
appetite and stomatitis (Table 2). Two patients experienced serious
treatment-related AEs, one of which led to the only discontinuation
due to a treatment-related AE (grade 2 interstitial lung disease).
There were no treatment-related deaths. Immune-mediated AEs,
which are reported regardless of attribution to treatment by the
investigator, occurred in 5 (19%) patients: grade 2 hypothyroidism
(n = 4), grade 3 drug-induced liver injury (n = 1), grade 2 interstitial
lung disease (n = 1), and grade 2 pneumonitis (n = 1).
3.3 | Efficacy
At the data cut-off, five patients had achieved a confirmed PR, for
an ORR of 19% (95% CI, 7%-39%); no patients achieved a CR
(Table 3). Another eight (31%) patients achieved stable disease, and
12 (46%) patients had a best response of PD. An additional patient
achieved an unconfirmed PR, for an ORR by investigator assessment
of 23% (95% CI, 9%-44%). When the analysis was restricted to
TABLE 1 Baseline demographics and disease characteristics of
patients with advanced head and neck squamous cell carcinoma
treated with pembrolizumab (Asia-Pacific all-patients-as-treated
population)
Characteristic n = 26
Age, years, median (range) 62 (44-73)
Male 22 (85)
ECOG PS
0 9 (35)
1 17 (65)
Smoking history
Current or former 19 (73)
Never 7 (27)
HPV status
HPV-associated 2 (8)
Non-HPV-associated 24 (92)
Sum of target lesions at baseline,
mm, median (range)
108 (21-269)
Primary tumor location
Hypopharynx 9 (35)
Oral cavity 5 (19)
Oropharynx 4 (15)
Larynx 4 (15)
Nasopharynx 2 (8)
Nasal cavity 1 (4)
External auditory canal 1 (4)
Combined positive score ≥1 22 (85)
Previous adjuvant and/or neoadjuvant therapy 12 (46)
Prior lines of systemic therapy, median (range) 3 (1-5)
No. of previous lines of therapy for recurrent or metastatic disease
0 4 (15)
1 6 (23)
2 4 (15)
≥3 12 (46)
Progressed after platinum treatment 24 (92)
HPV, human papillomavirus; PS, performance status.
Data are given as n (%) unless otherwise stated.
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patients who progressed after platinum-based therapy (n = 24), a
confirmed ORR of 17% (95% CI, 5%-37%) was observed (Table 3).
When the analysis was restricted to the 22 patients whose tumors
expressed PD-L1 (CPS ≥1), the ORR was 23% (95% CI, 8%-45%).
Overall, a reduction in target lesion size was observed in 50% of
patients, and most reductions were maintained over several imaging
assessments (Figure 1A,B).
The median time to response was 1.9 months (range, 1.6-
3.5 months) (Figure 1C). At the data cut-off, the median DOR was
not reached (range, 6 to 17+ months), four out of five responses
had lasted ≥6 months (Kaplan–Meier estimate), and 80% of
responses were ongoing.
The median PFS was 2.1 months (95% CI, 1.9-5.4). The PFS
rates at 6 and 12 months were 20% and 16%, respectively. Median
OS was 11.6 months (95% CI, 4.7-17.7). The 6-month OS rate was
59%, and the 12-month OS rate was 46% (Figure 1D).
4 | DISCUSSION
Head and neck squamous cell carcinoma is particularly burdensome
in the Asia-Pacific region, where cultural factors combine with tradi-
tional risk factors to increase the incidence of HNSCC compared
with the rest of the world.1,4-6 Pembrolizumab was well tolerated
and displayed durable antitumor activity in patients with HNSCC
from the Asia-Pacific region enrolled in the HNSCC expansion
cohort of KEYNOTE-012. The large majority of treatment-related
AEs were of grade 1 or 2 severity. Only two patients experienced a
grade 3 treatment-related AE, and no deaths were attributed to a
treatment-related event. Additionally, the safety profile of pem-
brolizumab in the Asia-Pacific subgroup was similar to that reported
previously with pembrolizumab in other malignancies, and no new
safety risks were identified.17-22
Efficacy outcomes in the Asia-Pacific subpopulation were similar
to those observed in the total expansion cohort and the initial
HNSCC cohort; the ORR among Asia-Pacific patients was 19%, com-
pared with 18% seen in the expansion and initial cohorts.12,13 Also
similar to both initial and total expansion cohorts, responses were
durable in the Asia-Pacific subpopulation, with the DOR in patients
in the Asia-Pacific region being not reached at the time of data cut-
off, and 80% of responses were still ongoing.12,13 Therefore, similar
to what has been reported previously, the present study results were
not impacted by ethnicity, and Asian patients had similar clinical out-
comes to the global study population.12,13,23
TABLE 2 Treatment-related adverse events (AEs) by grade
severity in patients with advanced head and neck squamous cell
carcinoma treated with pembrolizumab (Asia-Pacific all-patients-as-
treated population, n = 26)
Treatment-related AE Any grade occurring in ≥2 patients
Patients with ≥1 event 16 (62)
Fatigue 5 (19)
Decreased appetite 5 (19)
Hypothyroidism 4 (15)
Rash 4 (15)
Pyrexia 3 (12)
Dry skin 2 (8)
Lung infection 2 (8)
Anemia 2 (8)
Decreased lymphocytes 2 (8)
Hypercalcemia 2 (8)
Grade 3a occurring in ≥1 patient
Patients with ≥1 event 2 (8)
Stomatitis 1 (4)
Infection 1 (4)
Decreased appetite 1 (4)
aThere were no treatment-related AEs of grade 4 or 5 severity. Data are
shown as n (%).
TABLE 3 Antitumor activity of pembrolizumab in patients with advanced head and neck squamous cell carcinoma (Asia-Pacific all-patients-
as-treated population)
Response evaluation
Responses per RECIST version 1.1
by central imaging vendor review
Responses per RECIST version 1.1
by investigator assessment
All patients, n = 26
Progressed following prior
platinum treatment, n = 24 All patients, n = 26
n % (95% CI) n % (95% CI) n % (95% CI)
ORR 5 19 (7-39) 4 17 (5-37) 6 23 (9-44)
CR 0 0 (0-0) 0 0 (0-0) 0 0 (0-0)
PR 5 19 (7-39) 4 17 (5-37) 6 23 (9-44)
SD 8 31 (14-52) 8 33 (16-55) 9 35 (17-56)
PD 12 46 (27-67) 11 46 (26-67) 10 39 (20-59)
NAa 1 4 (<1-20) 1 4 (<1-21) 1 4 (<1-20)
CI, confidence interval; CR, complete response; NA, not assessed; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable
disease.
aPatient had no postbaseline imaging.
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The efficacy and safety of pembrolizumab in patients with
HNSCC is similar to what has been reported with another anti-PD-1
inhibitor, nivolumab. During the phase III CheckMate-141 study,
13% of patients with HNSCC responded to nivolumab.10 The fre-
quency and type of AEs seen with nivolumab during CheckMate-
141 were also similar to those observed with pembrolizumab in
HNSCC.10 However, the specific outcomes of the Asia-Pacific sub-
group from CheckMate-141 have not been reported, precluding the
comparison of these anti-PD-1 inhibitors in that patient population.
Likewise, few studies have reported specifically on treatment
outcomes in patients from the Asia-Pacific region with advanced
HNSCC, making it difficult to compare our results with other therapy
options. However, the median OS with pembrolizumab in the pre-
sent study (11.6 months) was similar to that reported in patients
from China and Korea who were treated with the recommended
first-line regimen of cisplatin/5-fluorouracil plus cetuximab
(13 months).24 Despite the heavily pretreated population in our
study, the toxicity of pembrolizumab was notably better than the
platinum and cetuximab regimen (grade 3-4 treatment-related AEs,
8% vs 44%).24 A head-to-head comparison of pembrolizumab vs this
standard first-line treatment regimen is underway in the phase III
KEYNOTE-048 trial (ClinicalTrials.gov, NCT02358031).
The results presented here add to a growing body of evidence
supporting the use of pembrolizumab in patients with HNSCC.12,13,15
This subgroup analysis is limited by the small number of patients
enrolled from the Asia-Pacific region, and the results should there-
fore be interpreted with this limitation in mind. Ongoing phase III tri-
als are being undertaken worldwide, including in the Asia-Pacific
region, to further investigate the efficacy and safety of pem-
brolizumab in advanced HNSCC. Subgroup analyses of Asia-Pacific
patients in these trials are needed to confirm the clinical utility of
pembrolizumab to treat HNSCC in this region of the world.
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F IGURE 1 Efficacy of pembrolizumab, based on RECIST version 1.1 by central imaging vendor review. Data shown are the maximum
percentage change from baseline in target lesions (n = 25) (A), change from baseline in tumor size over time (n = 25) (B), treatment exposure
and response duration (n = 25) (C), and Kaplan–Meier estimate of overall survival (n = 26) (D). PD, progressive disease; PR, partial response
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